<DOC>
	<DOCNO>NCT02872285</DOCNO>
	<brief_summary>The objective Phase 2 trial determine efficacy safety LYC-30937-EC patient moderate plaque-type psoriasis .</brief_summary>
	<brief_title>An Efficacy Safety Study LYC-30937-EC Subjects With Moderate Chronic Plaque-type Psoriasis</brief_title>
	<detailed_description>Approximately 30 subject enrol double-blind , placebo-controlled study . The cohort stratify 2:1 , one cohorts placebo . The active cohort receive LYC-30937-EC 25 mg daily , demonstrate safety tolerability Phase I trial . The study design patient previously diagnose moderate chronic plaque-type psoriasis consist follow : - Screening period ( initials assessment eligibility score ) - Day 1 : confirm eligibility , baseline efficacy assessment ( PASI , IGA ) , randomize initiate dose - Week 2 : safety assessment include vital sign , body temperature , physical exam , clinical lab perform - Week 4 : efficacy ( PASI , IGA ) safety assessment include vital sign , body temperature , physical exam , clinical lab perform - Week 8 : efficacy ( PASI , IGA ) safety assessment include vital sign , body temperature , physical exam , clinical lab perform - Week 12 : final efficacy assessment ( PASI , IGA ) , safety assessment include vital sign , body temperature , physical exam , ECG , clinical lab perform - Week 14 : final safety assessment include vital sign , body temperature , clinical lab</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have diagnosis plaquetype psoriasis least 6 month prior screen . Must chronic moderate plaquetype psoriasis confirm screen baseline visit . Moderate plaquetype psoriasis define PASI &gt; 7 , BSA involvement 515 % inclusive overall lesion severity `` moderate '' `` mark , `` `` moderate '' = plaque elevation ( 0.75mm ) , moderate red coloration , coarse scale predominates ; `` mark '' = moderate plaque elevation ( 1.0mm ) , bright red coloration , thick , nontenacious scale predominates . Female subject childbearing potential must agree use two highly effective form contraception study participation 30 day last dose treatment study drug treatment . Male subject partner childbearing potential must take appropriate precaution avoid father child participate study use appropriate barrier contraception abstinence study 30 day last dose study drug . Agree avoid prolong sun exposure avoid tan booths ultraviolet ( UV ) light source study . Ability provide write informed consent compliant schedule event . Nonplaquetype psoriasis ( eg , pustular , erythrodermic , guttate psoriasis ) . Druginduced psoriasis ( ie , new onset current exacerbation betablockers , calcium channel blocker , lithium ) . Spontaneously improve rapidly deteriorate plaque psoriasis . Comorbid psoriatic arthritis amenable treatment NSAIDs . Treatment biologic agent psoriasis . Failed 2 systemic treatment plaque psoriasis . Received phototherapy prolong sun exposure use tan booth ultraviolet light source within 4 week initiate screening procedure . Received systemic drug therapy ( nonbiologic ) plaque psoriasis systemic medication could affect psoriasis evaluation ( PASI IGA ) , include limited oral injectable corticosteroid , retinoids , sulfasalazine , within 4 week initiate screening procedure . Received topical medication could affect psoriasis evaluation ( PASI IGA ) , include limited corticosteroid , retinoids , topical vitamin D derivative , picrolimus , tacrolimus , calcipotriene , within 2 week initiate screening procedure . Received immunosuppressant agent ( eg , cyclosporine , azathioprine , methotrexate ) within 8 week initiate screening procedure . Any following laboratory abnormality : 1. liver function test &gt; 1.5 x upper limit normal ( ULN ) direct bilirubin &gt; 1.5 x ULN 2. hemoglobin &lt; 8.5 g/dl ( international system unit [ SI ] : &lt; 85 g/L ) 3. neutrophil &lt; 1500/mm3 ( SI : &lt; 1.5 x 109/L ) 4. white blood cell ( WBC ) count &lt; 3,000/mm3 ( SI : &lt; 3.0 x 109/L ) 5. platelet &lt; 80,000 mm3 ( SI : 80 x 109/L ) 6. international normalize ratio ( INR ) &gt; 1.5 7. serum creatinine &gt; 1.4 mg/dL woman &gt; 1.6 mg/dL men Clinically relevant hepatic , neurological , pulmonary , dermatological , ophthalmological , gastrointestinal , endocrine , psychiatric , major systemic disease make implementation protocol interpretation study difficult would put subject risk participate study . History currently active primary secondary immunodeficiency . Treatment investigational agent within 30 day prior initiate screen procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>